Who Owns Insulet Company?

Insulet Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Insulet Corporation?

Understanding Insulet's ownership is key to grasping its strategic direction. The company went public in May 2007, expanding its investor base and access to capital.

Founded in 2000, Insulet is a leader in diabetes management, known for its innovative Omnipod Insulin Management System. The company achieved over $2 billion in revenue in 2024.

As of July 2025, Insulet has a market cap of about $20.16 billion. This exploration will cover Insulet's ownership history, key stakeholders, and recent trends, including the impact of its Insulet Porter's Five Forces Analysis on its market position.

Insulet Corporation was founded in 2000 by John Brooks, Amparo Diaz, and Duane DeSisto. Their vision was to create a more user-friendly insulin delivery system, inspired by a father's desire to improve diabetes management for his son. This foundational drive aimed to revolutionize how individuals manage their condition.

Founding Team John Brooks, Amparo Diaz, and Duane DeSisto established Insulet in 2000. Their collective expertise and shared vision were instrumental in the company's inception. Initial Funding In 2001, Insulet secured $5 million in venture capital. This crucial funding enabled the company to advance its product development efforts. Product Development The initial capital infusion supported the development of the Omnipod system, which began in 2003. This innovative, tubeless design aimed to simplify insulin delivery. Early Ownership Details Specifics regarding the founders' initial equity splits or shareholding percentages are not publicly disclosed. Information on early ownership disputes or buyouts is also unavailable. Visionary Approach The founders' commitment to innovation was evident in their focus on a user-friendly, tubeless insulin delivery system. This approach directly addressed the limitations of traditional methods. Market Entry Preparation The early stages of Insulet were characterized by strategic development and funding acquisition. This laid the groundwork for the company's eventual market presence.

The founding team's dedication to improving diabetes care was the driving force behind Insulet's establishment. Their focus on creating a novel, tubeless insulin delivery system, the Omnipod, marked a significant departure from existing technologies. This innovative spirit, coupled with early venture capital, set the stage for the company's future growth and its impact on the Target Market of Insulet.

Founders and Early Ownership

Insulet Corporation's ownership structure began with its founders: John Brooks, Amparo Diaz, and Duane DeSisto, who established the company in 2000. The company's early development was significantly supported by a $5 million venture capital investment secured in 2001, which was crucial for initiating the development of the Omnipod system in 2003.

• Founding Year: 2000
• Founders: John Brooks, Amparo Diaz, Duane DeSisto
• Initial Venture Capital: $5 million in 2001
• Key Product Development: Omnipod system (initiated 2003)
• Publicly Traded Status: Insulet is a publicly traded company, meaning its stock is available for purchase on an exchange.
• Insulet's market capitalization as of late 2023 and early 2024 has seen significant fluctuations, reflecting investor sentiment and market conditions.

Insulet SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Insulet Corporation's journey as a publicly traded entity began with its Initial Public Offering (IPO) on May 15, 2007, on the Nasdaq Global Market under the ticker 'PODD'. The IPO saw the offering of 7,700,000 shares at $15.00 per share, establishing an initial market capitalization of approximately $393.10 million. This transition marked a significant step in its ownership evolution.

The ownership structure of Insulet Corporation has significantly evolved since its IPO, with a pronounced shift towards substantial institutional investor holdings. As of July 2025, the company boasts a market capitalization of approximately $20.16 billion, a testament to its growth and market presence. The majority of Insulet stock is held by institutional investors, with their collective ownership reported to be over 100% as of March 31, 2025. This high level of institutional ownership is often seen as a positive signal, suggesting strong confidence from major financial players in the company's future prospects and stability.

Insulet's Major Stakeholders

Institutional investors are the primary owners of Insulet Corporation, holding a significant majority of its shares. This concentration of ownership among large financial entities influences the company's strategic direction and governance.

• Vanguard Group Inc. is a leading shareholder, holding 8,668,952 shares, representing 12.09% of the equity.
• Fidelity Management & Research Co. LLC (Fmr Llc) holds 7,915,742 shares, accounting for 11.07% of the company's equity.
• BlackRock, Inc. (BlackRock Advisors LLC) owns 6,409,148 shares, representing 6.939% of the equity.
• Capital Research Global Investors holds 6,076,540 shares, which is 10.6% of the company's equity.
• State Street Corp possesses 3,023,509 shares, making up 4.236% of the total equity.
• Baillie Gifford & Co holds 2,250,755 shares.
• Corporate insiders collectively own 0.39% of the company's stock as of May 2025.

Understanding these Insulet major shareholders is crucial for grasping the dynamics of Insulet stock ownership and the broader Insulet company stakeholders. For a deeper dive into the competitive environment, explore the Competitors Landscape of Insulet.

Insulet PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Insulet Corporation's Board of Directors is responsible for guiding the company's strategic direction and governance. As of July 2025, Timothy Scannell serves as Chairman of the Board. Ashley McEvoy took on the roles of President and Chief Executive Officer, and joined the Board on April 28, 2025, succeeding Jim Hollingshead.

Insulet Corporation's voting power is primarily distributed through its common stock, which operates on a one-share-one-vote principle. This means each share of common stock held by a shareholder entitles them to one vote. There is no public information suggesting the existence of dual-class shares or other structures that would concentrate voting power disproportionately among specific individuals or entities. While specific details on recent shareholder activism are not publicly detailed, the significant presence of institutional investors indicates their potential influence on company decisions through their substantial stock holdings and engagement.

Understanding Insulet's Shareholder Landscape

The ownership structure of Insulet Corporation is largely influenced by its institutional investors. These entities often hold significant blocks of shares, impacting corporate governance and strategic decisions.

• Institutional investors are key stakeholders in Insulet Corporation.
• The company operates on a one-share-one-vote system for common stock.
• There is no public indication of controlling ownership by founders or specific share classes.
• Understanding Growth Strategy of Insulet can provide context for shareholder interests.

Insulet Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Insulet Corporation has seen significant shifts in its leadership and ownership structure over the past few years, reflecting dynamic market engagement. A key development was the appointment of Ashley McEvoy as CEO in April 2025, succeeding Jim Hollingshead, as the company gears up for international expansion of its Omnipod 5 system.

The board of directors also saw new additions in January 2024 with Flavia Pease and Timothy Stonesifer joining, while Shacey Petrovic and Corinne Nevinny retired in May 2024. These changes occur amidst a landscape where institutional investors remain the primary Insulet stock ownership group, actively managing their portfolios. The company anticipates exceeding its first-quarter revenue guidance for 2025 and plans to increase its full-year projections, indicating strong investor confidence in Insulet's growth strategy within the diabetes care sector. This proactive approach to financial reporting and investor relations highlights the company's commitment to transparency regarding its Insulet company structure ownership.

Leadership Transition Impact

The recent CEO transition is expected to drive further international growth for Insulet. Ashley McEvoy's expertise is seen as crucial for the planned expansion of Omnipod 5.

Institutional Investor Activity

Significant increases in holdings by major institutional investors signal strong conviction in Insulet's market position. This active management reflects confidence in the company's future performance.

Board Composition Evolution

Changes in board membership aim to bring fresh perspectives and expertise. The addition of new directors complements the company's strategic direction.

Positive Financial Outlook

Insulet's expectation to surpass revenue guidance and raise full-year projections underscores its robust financial health. This outlook is a key indicator for Insulet stock ownership trends.

Insulet Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔